Filed: 5/13/2025ACC: 0000950123-25-004926
📋 What this filing means
SR ONE CAPITAL MANAGEMENT, LP filed this quarterly 13F‑HR report disclosing 12 equity positions with a total reported market value of $389.28M. This filing provides a transparent view of the manager's long equity holdings as of the quarter end.
12
Positions
$389.28M
Total AUM (reported)
29.37M
Total Shares
Allocation by class
COMMON STOCK$344.10M88.4%
COMMON SHARES$39.05M10.0%
ORDINARY SHARES$6.14M1.6%
Portfolio Concentration
Top 3$254.09M65.3%
4–10$128.41M33.0%
11–25$6.78M1.7%
Top 3 weight
65.3%
Top 10 weight
98.3%
Voting Authority Distribution
Total shares with voting rights: 29.37M
Sole
Full voting authority
29.37M
shares
% of voting shares100.0%
Shared
Joint voting authority
0.00
shares
% of voting shares0.0%
None
No voting authority
0.00
shares
% of voting shares0.0%
Investment Discretion (by position count)
Sole12
Shared0
Other0
Dominant voting typeSole · 100.0% of voting shares
Institutional Holdings12
Rows:
Arcellx, Inc.
SOLEShares2.35M
TypeSH
Market value$153.94M
39.54%
Sole
2.35M
Shared
0.00
None
0.00
ARS Pharmaceuticals, Inc.
SOLEShares4.01M
TypeSH
Market value$50.48M
12.97%
Sole
4.01M
Shared
0.00
None
0.00
Mineralys Therapeutics Inc.
SOLEShares3.13M
TypeSH
Market value$49.67M
12.76%
Sole
3.13M
Shared
0.00
None
0.00
Zenas BioPharma, Inc
SOLEShares4.91M
TypeSH
Market value$38.80M
9.97%
Sole
4.91M
Shared
0.00
None
0.00
CRISPR Therapeutics AG
SOLEShares1.05M
TypeSH
Market value$35.70M
9.17%
Sole
1.05M
Shared
0.00
None
0.00
Design Therapeutics, Inc.
SOLEShares6.53M
TypeSH
Market value$25.19M
6.47%
Sole
6.53M
Shared
0.00
None
0.00
Alumis Inc.
SOLEShares1.96M
TypeSH
Market value$12.03M
3.09%
Sole
1.96M
Shared
0.00
None
0.00
Oculis Holding AG
SOLEShares322.50K
TypeSH
Market value$6.14M
1.58%
Sole
322.50K
Shared
0.00
None
0.00
Nkarta, Inc.
SOLEShares3.33M
TypeSH
Market value$6.13M
1.58%
Sole
3.33M
Shared
0.00
None
0.00
Oruka Therapeutics, Inc
SOLEShares430.33K
TypeSH
Market value$4.42M
1.13%
Sole
430.33K
Shared
0.00
None
0.00
KALA Bio, Inc.
SOLEShares598.94K
TypeSH
Market value$3.43M
0.88%
Sole
598.94K
Shared
0.00
None
0.00
enGene Holdings Inc.
SOLEShares747.75K
TypeSH
Market value$3.35M
0.86%
Sole
747.75K
Shared
0.00
None
0.00
| Issuer | Class | Shares | Type | Value / Portfolio % | Voting — Sole | Shared | None |
|---|---|---|---|---|---|---|---|
Arcellx, Inc.SOLE | Common Stock | 2.35M | SH | $153.94M 39.54% | 2.35M | 0.00 | 0.00 |
ARS Pharmaceuticals, Inc.SOLE | Common Stock | 4.01M | SH | $50.48M 12.97% | 4.01M | 0.00 | 0.00 |
Mineralys Therapeutics Inc.SOLE | Common Stock | 3.13M | SH | $49.67M 12.76% | 3.13M | 0.00 | 0.00 |
Zenas BioPharma, IncSOLE | Common Stock | 4.91M | SH | $38.80M 9.97% | 4.91M | 0.00 | 0.00 |
CRISPR Therapeutics AGSOLE | Common Shares | 1.05M | SH | $35.70M 9.17% | 1.05M | 0.00 | 0.00 |
Design Therapeutics, Inc.SOLE | Common Stock | 6.53M | SH | $25.19M 6.47% | 6.53M | 0.00 | 0.00 |
Alumis Inc.SOLE | Common Stock | 1.96M | SH | $12.03M 3.09% | 1.96M | 0.00 | 0.00 |
Oculis Holding AGSOLE | Ordinary Shares | 322.50K | SH | $6.14M 1.58% | 322.50K | 0.00 | 0.00 |
Nkarta, Inc.SOLE | Common Stock | 3.33M | SH | $6.13M 1.58% | 3.33M | 0.00 | 0.00 |
Oruka Therapeutics, IncSOLE | Common Stock | 430.33K | SH | $4.42M 1.13% | 430.33K | 0.00 | 0.00 |
KALA Bio, Inc.SOLE | Common Stock | 598.94K | SH | $3.43M 0.88% | 598.94K | 0.00 | 0.00 |
enGene Holdings Inc.SOLE | Common Shares | 747.75K | SH | $3.35M 0.86% | 747.75K | 0.00 | 0.00 |